Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH

Hepatology

Volumn 59, Issue 3, 2014, Pages 886-897

  Sutti, Salvatore ^a   Jindal, Aastha ^a   Locatelli, Irene ^a   Vacchiano, Marco ^a   Gigliotti, Luca ^a   Bozzola, Cristina ^a   Albano, Emanuele ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; AMINOTRANSFERASE; BOVINE SERUM ALBUMIN; CHOLINE; IMMUNOGLOBULIN G; INTERLEUKIN 15; MALONALDEHYDE; METHIONINE; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME RELEASE; IMMUNIZATION; INFLAMMATION; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE; MALE; MOUSE; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION;

ADAPTIVE IMMUNITY; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; HUMANS; KILLER CELLS, NATURAL; LIPID PEROXIDATION; LIVER; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS;

EID: 84896722464     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26749     Document Type: Article

References (49)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350.
2. Marra F, Gastaldelli A, Svegliati-Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72-81.
3. Tilg H, Mochen AR. Evolution of inflammation in non-alcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846.
4. Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2011;15:1325-1365.
5. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 2002;37:56-62.
6. Chalasani N, Deeg MA, Crabb DW. Systemic lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-14502.
7. Miller YI, Choi SH, Weisner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011;108:235-248.
8. Weismann D, Binder CJ. The innate immune response to products of phospholipid peroxidation. Biochim Biophys Acta 2012;1818:2465-2475.
9. Palinski W, Witztum JL. Immune response to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Int Med 2000;247:171-180.
10. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified antigens. Autoimmun Rev 2008;7:567-573.
11. Nobili V, Parola M, Alisi A, Marra F, Piemonte F, Mombello C, et al. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Int J Molec Med 2010;26:471-476.
12. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino D, et al. Immune response toward lipid peroxidation products as a predictor of the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. Gut 2005;54:987-993.
13. Larter CZ, Yeh MM. Animal model of NASH: getting both pathology and metabolic contest right. J Gastroenterol Hepatol 2008;23:1635-1648.
14. Rolla R, Vidali M, Serino R, Pergolini P, Albano E, Bellomo G. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. Clin Exp Immunol 2007;149:63-69
15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
16. Locatelli I, Sutti S, Vacchiano M, Bozzola C, Albano E. NF-kB1 deficiency stimulates the progression of nonalcoholic steatohepatitis (NASH) in mice by promoting NKT-mediated responses. Clin Sci (Lond) 2013;124:279-287.
17. + T cells. Cytometry 2000;40:60-68.
18. Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Verheyen F, Buurman WA, et al. Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 2012;56:894-903.
19. Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 2009;21:257-264.
20. Li Z, Soloski MK, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005;42:880-885.
21. Kremer M, Thomas E, Milton RJ, Perry AW, van Rooijen N, Wheeler MD, et al. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010;51, 130-141.
22. Tang ZH, Liang S, Potter J, Jiang X, Mao HQ, Li Z. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol 2013;190:1788-1796.
23. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012;61:1323-1329.
24. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, et al. Osteopontin, an oxidant stress-sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K-pAkt-NFκB signaling. Hepatology 2012;55:594-608.
25. Kaminski D, Randall TD. Adaptive immunity and adipose tissue biology. Trends Immunol 2010;31:384-390.
26. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related adipose tissue inflammation. Diabetology 2012;55:2583-2592.
27. Brunt EM. Pathology of non-alcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.
28. Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJJ. N-acethylcysteine attenuates progression of liver pathology in a rat model of non-alcoholic steatohepatitis. J Nutr 2008;138:1872-1879.
29. Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 2013;58:801-810.
30. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519.
31. Poggi M, Engel D, Christ A, Beckers L, Wijnands E, Boon L, et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol 2011;31:2251-2260.
32. Inzaugarat ME, Ferreyra Solari NE, Billordo LA, Abecasis R, Gadano AC, Cherñavsky AC. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. J Clin Immunol 2011;31:1120-1130.
33. Ferreyra Solari NE, Inzaugarat ME, Baz P, De Matteo E, Lezama C, Galoppo M, et al. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol 2012;32:611-621.
34. DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A 2013;110:5133-5138.
35. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005;115:3072-3082.
36. Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, Kehry M, et al. B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology 2011;53:527-535.
37. Santodomingo-Garzon T, Swain MG. Role of NKT cells in autoimmune liver disease. Autoimmun Rev 2011;10:793-800.
38. Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta 2012 [Epub ahead of print].
39. Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, et al. Accumulation of natural killer T cells in progressive non-alcoholic fatty liver disease. Hepatology 2010;51:1998-2007.
40. + natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009;21:673-680.
41. Di Sabatino A, Calarota SA, Vidali F, MacDonald TT, Corazza GR. Role of IL-15 in immune and infectious diseases. Cytokine Growth Factor Rev 2011;22:19-33.
42. + T cell differentiation. J Immunol 2009;182:6149-6159.
43. Suzuki A, McCall S, Choi SS, Sicklick JK, Huang J, Qi Y, et al. Interleukin-15 increases hepatic regenerative activity. J Hepatol 2006;45:410-418.
44. Uede T. Osteopontin intrinsic tissue regulator of intractable inflammatory disease. Pathol Int 2011;61:265-280.
45. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004;21:539-550
46. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-115.
47. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004;287:G264-G273.
48. Ritting SR. Osteopontin in macrophage functions. Exp Rev Mol Med 2011;13:e15.
49. Rangnekar AS, Lammert F, Igolnikov A, Green RM. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int 2006;26:1000-1005.